SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-073902
Filing Date
2022-11-18
Accepted
2022-11-18 17:15:24
Documents
16
Period of Report
2022-11-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea169000-8k_tffpharma.htm   iXBRL 8-K 46660
2 UNDERWRITING AGREEMENT DATED AS OF NOVEMBER 17, 2022 BETWEEN THE COMPANY AND JON ea169000ex1-1_tffpharma.htm EX-1.1 228165
3 FORM OF WARRANT SOLD IN THE OFFERING ea169000ex4-1_tffpharma.htm EX-4.1 96153
4 OPINION OF GREENBERG TRAURIG, LLP ea169000ex5-1_tffpharma.htm EX-5.1 7757
5 PRESS RELEASE DATED NOVEMBER 18, 2022 REGARDING PRICING OF THE OFFERING OF COMMO ea169000ex99-1_tffpharma.htm EX-99.1 5677
  Complete submission text file 0001213900-22-073902.txt   642115

Data Files

Seq Description Document Type Size
6 XBRL LABEL FILE tffp-20221117_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE tffp-20221117_pre.xml EX-101.PRE 22361
8 XBRL SCHEMA FILE tffp-20221117.xsd EX-101.SCH 3288
10 EXTRACTED XBRL INSTANCE DOCUMENT ea169000-8k_tffpharma_htm.xml XML 3702
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 221402808
SIC: 2834 Pharmaceutical Preparations